# Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation

> **NCT01326273** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Imperial College London**

## Conditions studied

- CMV Reactivation
- Allogeneic Stem Cell Transplantation
- Autologous CMV Specific CD8+ T Cells

## Interventions

- **PROCEDURE:** Lymphopheresis
- **PROCEDURE:** CMV specific lymphocyte infusion
- **PROCEDURE:** Peripheral blood for CMV DNA PCR
- **PROCEDURE:** Haematology/Blood chemistry

## Key facts

- **NCT ID:** NCT01326273
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326273, "Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01326273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*